Equity Research
William Blair research analyst Sami Corwin was quoted in BioSpace in its story about policy changes by the FDA that will make cancer cell therapy drugs more accessible.
“We view the removal of the REMS program for CAR-T cell therapies as a positive development for the space, as it supports the notion that the FDA is working to minimize red tape and increase access to potentially curative treatments for patients,” Corwin wrote in a note to investors that was cited by the publication.
Stay up-to-date with the latest William Blair news and insights
Chair Powell’s comments at the press conference for the latest FOMC meeting highlight one of the biggest challenges for the Fed (and financial market participants) at the moment—deciding how much of the slowdown in the labor market is due to a shortage in the supply of workers and how much is due to softening demand.
In a recent report by William Blair’s Brian Drab and Trevor Sahr, we highlight global problems related to water, including water scarcity, aging infrastructure, and water quality and contamination. The report also details several solutions that we believe are critical to addressing these problems.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
